HAYA Therapeutics | HAYA Therapeutics Announces Collaboration …

Sep 4, 2024 · LAUSANNE, Switzerland and SAN DIEGO, USA – Sept. 4, 2024 – HAYA Therapeutics, SA, a biotechnology company pioneering precision RNA-guided regulatory …

CouponFollow Extension

$3
OFF

Eli Lilly And HAYA Therapeutics Enter Metabolic Condition …

4 weeks from now

Sep 6, 2024 · Lilly has made a series of deals this year, including its acquisition of Morphic Therapeutics for approximately $3.2bn. The agreement, which closed last month, gave Lilly …

pmlive.com

$1
OFF

Lilly Partners With Haya For LncRNA Obesity Target Deal Worth $1bn

4 weeks from now

Sep 5, 2024 · Pharma giant Eli Lilly is teaming up with Haya Therapeutics in a $1bn deal to find multiple regulatory-genome-derived RNA-based drug targets, as it eyes up new targets in …

pharmaceutical-technology.com

98%
OFF

HAYA, Lilly Launch Up-to-$1B Metabolic Collaboration

4 weeks from now

Sep 4, 2024 · The noncoding portion that makes up 98% of the human genome is anything but “junk” to HAYA Therapeutics, which said it is partnering with Eli Lilly to identify multiple …

genengnews.com

$1
OFF

Lilly, Haya Ink $1B Biobuck Obesity Pact To Search Dark Genome

4 weeks from now

Sep 4, 2024 · Eli Lilly’s hunt for obesity targets has led it to the dark genome. The Big Pharma has put together a deal worth up to $1 billion in biobucks to partner with Haya Therapeutics to find …

fiercebiotech.com

98%
OFF

HAYA, Lilly Launch Up-to-$1B Metabolic Collaboration

4 weeks from now

Sep 4, 2024 · Samir Ounzain, PhD, co-founder and CEO of HAYA Therapeutics. The noncoding portion that makes up 98% of the human genome is anything but “junk” to HAYA Therapeutics, …

sdbn.org

$1
OFF

Lilly, Haya Ink Potential $1B Drug Discovery Deal To Target

4 weeks from now

Sep 4, 2024 · Eli Lilly is diving further into the obesity space with a potential billion-dollar deal with Haya Therapeutics. The companies announced a collaboration Wednesday to utilize the Swiss …

biospace.com

$1
OFF

Lilly Taps RNA Biotech For $1 Billion Weight-loss Collaboration

4 weeks from now

Sep 4, 2024 · The Lilly-Haya deal marks the second Big Pharma collaboration in as many weeks to focus on lncRNAs. Bayer recently agreed to pay NextRNA Therapeutics up to $547 million …

acs.org

$1
OFF

HAYA Therapeutics: Collaboration With Lilly Valued Up To $1 …

4 weeks from now

Sep 6, 2024 · HAYA Therapeutics - a biotechnology company pioneering precision RNA-guided regulatory genome targeting therapeutics for chronic diseases - announced a multi-year …

pulse2.com

FAQs about HAYA Therapeutics | HAYA Therapeutics Announces Collaboration … Coupon?

Could Haya get $1bn from Eli Lilly?

Haya could secure up to $1bn after hitting preclinical, clinical, and commercial milestones with drugs that emerge from this deal. Eli Lilly and Haya Therapeutics aim to find multiple regulatory genome derived RNA-based drug targets for obesity. Credit: eamesBot via Shutterstock. ...

Does Eli Lilly have a dark genome?

Eli Lilly’s hunt for obesity targets has led it to the dark genome. The Big Pharma has put together a deal worth up to $1 billion in biobucks to partner with Haya Therapeutics to find multiple regulatory-genome-derived RNA-based drug targets. ...

What is Haya Therapeutics?

About HAYA Therapeutics HAYA Therapeutics is a precision medicines company developing programmable therapeutics targeting regulatory RNAs derived from the dark genome, a cell information processing unit, to reprogram pathological cell states for a broad range of diseases, including cardiovascular and metabolic diseases and cancer. ...

Why is Lilly partnering with a biopharma?

For Lilly, the collaboration marks interest in yet another approach to fighting metabolic disorders. The Indianapolis-based biopharma launched the world’s first commercially available insulin product for diabetes control in humans in 1923. ...

What is Haya's lead therapeutic candidate?

HAYA’s lead therapeutic candidate is HTX-001, in development for the treatment of heart failure. HAYA is also developing a pipeline of lncRNA-targeting precision therapies for the cell-specific treatment of diseases in other tissues. ...

Does Lilly have a target for obesity?

It comes as no surprise that Lilly is eyeing up new targets in obesity, as it is one of the frontrunners in the space. Its blockbuster drug tirzepatide, which is marketed as Mounjaro for type 2 diabetes and Zepbound for obesity is the main competitor for Novo Nordisk ’s semaglutide versions, Ozempic and Wegovy. ...